Response to Induction Neoadjuvant Hormonal Therapy Using Upfront 21-Gene Breast Recurrence Score Assay-Results From the SAFIA Phase III Trial.
Khalid AlsalehHeba Al ZahwahryAdda BounedjarMohammed OukkalAhmed SaadeddineHassen MahfoufKamel BouzidAssia BensalemTaha FilaliHikmat Abdel-RazeqBlaha LarbaouiAlaa KandilOmalkhair AbulkhairMeteb Al-FoheidiHassan ErrihaniMarwan GhosnNashwa Abdel-AzizMaria A ArafahHamouda BoussenFarida DabouzHaleem RasoolMohun BahadoorJihen AyariSharif KullabJean-Marc NabholtzPublished in: JCO global oncology (2021)
The upfront 21-gene assay performed on biopsies is feasible in our population and has allowed us to select patients with high hormone sensitivity (RS < 31). This approach could be an alternative to upfront surgery without significant risk of progression, particularly during pandemic times.
Keyphrases
- phase iii
- open label
- clinical trial
- phase ii
- high throughput
- copy number
- genome wide
- minimally invasive
- double blind
- placebo controlled
- coronavirus disease
- sars cov
- rectal cancer
- lymph node
- genome wide identification
- locally advanced
- coronary artery bypass
- stem cells
- metabolic syndrome
- mesenchymal stem cells
- gene expression
- genome wide analysis
- randomized controlled trial
- polycystic ovary syndrome
- adipose tissue
- dna methylation
- percutaneous coronary intervention
- surgical site infection
- replacement therapy